✦ LIBER ✦

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

✍ Scribed by María-Victoria Mateos; Albert Oriol; Joaquín Martínez-López; Norma Gutiérrez; Ana-Isabel Teruel; Raquel de Paz; José García-Laraña; Enrique Bengoechea; Alejandro Martín; Joaquín Díaz Mediavilla; Luis Palomera; Felipe de Arriba; Yolanda González; Jose-Mariano Hernández; Ana Sureda; José-Luis Bello; Joan Bargay; Francisco-Javier Peñalver; José-María Ribera; María-Luisa Martín-Mateos; Ramón García-Sanz; María-Teresa Cibeira; María-Luisa Martín Ramos; María-Belén Vidriales; Bruno Paiva; María-Angeles Montalbán; Juan-José Lahuerta; Joan Bladé; Jesús-Fernando San Miguel

Book ID: 117785443
Publisher: The Lancet
Year: 2010
Tongue: English
Weight: 255 KB
Volume: 11
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(10)70187-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Maintenance therapy with bortezomib plus

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

✍ Mateos, M.-V.; Oriol, A.; Martinez-Lopez, J.; Gutierrez, N.; Teruel, A.-I.; Lope 📂 Article 📅 2012 🏛 American Society of Hematology 🌐 English ⚖ 269 KB

Bortezomib Plus Melphalan and Prednisone

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

✍ Mateos, M. V.; Richardson, P. G.; Schlag, R.; Khuageva, N. K.; Dimopoulos, M. A. 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 493 KB

Melphalan and prednisone plus thalidomid

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

✍ Thierry Facon; Jean Yves Mary; Cyrille Hulin; Lotfi Benboubker; Michel Attal; Br 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 183 KB

PSY19 THE COST-EFFECTIVENESS OF BORTEZOM

PSY19 THE COST-EFFECTIVENESS OF BORTEZOMIB PLUS MELPHALAN AND PREDNISONE VERSUS LENALIDOMIDE PLUS MELPHALAN AND PREDNISONE WITH CONTINUOUS LENALIDOMIDE MAINTENANCE TREATMENT FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES

✍ S.T. Wang; H. Huang; A. Ba-mancini; H. Shi; K. Chen; C. Korves; R. Dhawan; A. Ca 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

“Short Course” Bortezomib plus Melphalan

“Short Course” Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma

✍ Cristina Gasparetto; Jon P. Gockerman; Louis F. Diehl; Carlos M. de Castro; Jose 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 382 KB

Thalidomide versus bortezomib based regi

Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: A systematic review

✍ Ambuj Kumar; Iztok Hozo; Keath Wheatley; Benjamin Djulbegovic 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 542 KB